Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 dia-betes (AWARD-9)
The Expanding Challenge of Emerging Biologics Peptides are an example of a broader trend
It also limits fat-storing signals like excess glucagon
Our biggest critique is on the pricing on their products page
The results of the threshold analysis revealed that, under the base-case assumptions, GLP-1 RAs would be cost-effective at an annual cost of AU$450 in the total population and AU$500 in the secondary prevention population
US$ 23.86
US$ 25.73
US$ 21.38
US$ 23.56
US$ 29.94
US$ 21.61
US$ 29.63
